e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Cost-effectiveness in diagnosis, therapy and care
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Is treatment with ICS and LABA good value for money for COPD? Multinational cost-effectiveness analysis of the TORCH study
H. Glick, A. Briggs, G. Lozano-Ortega, M. Spencer, P. Calverley, J. Vestbo (Philadelphia, United States Of America; Glasgow, Greenford, Liverpool, Manchester, United Kingdom; Vancouver, Canada)
Source:
Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care
Session:
Cost-effectiveness in diagnosis, therapy and care
Session type:
Thematic Poster Session
Number:
1189
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Glick, A. Briggs, G. Lozano-Ortega, M. Spencer, P. Calverley, J. Vestbo (Philadelphia, United States Of America; Glasgow, Greenford, Liverpool, Manchester, United Kingdom; Vancouver, Canada). Is treatment with ICS and LABA good value for money for COPD? Multinational cost-effectiveness analysis of the TORCH study. Eur Respir J 2007; 30: Suppl. 51, 1189
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study
Source: Eur Respir J 2010; 35: 532-539
Year: 2010
Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009
Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020
1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
AUSTRI and VESTRI LABA Safety studies subgroup analysis of asthma exacerbations and SAEs comparing FSC and FP by ICS dose
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials
Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Year: 2019
Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
The cost-effectiveness of early intervention with inhaled budesonide once daily: an international comparison of the results from the START study
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002
Health care resource utilization following addition of montelukast or salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial)
Source: Eur Respir J 2004; 24: Suppl. 48, 127s
Year: 2004
COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data
Source: Eur Respir J 2007; 30: Suppl. 51, 612s
Year: 2007
Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
Source: ERJ Open Res, 8 (1) 00333-2021; 10.1183/23120541.00333-2021
Year: 2022
Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial
Source: Eur Respir J 2013; 41: 556-564
Year: 2013
Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials
Source: Annual Congress 2012 - Different ways to phenotype asthma
Year: 2012
The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014
A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013
Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design
Source: ERJ Open Res, 5 (4) 00061-2019; 10.1183/23120541.00061-2019
Year: 2019
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept